In the Boardroom
Refine search
Biotechnology
Canadian genetic medicines company enGene Therapeutics announced changes to its board of directors as it prepares for potential regulatory milestones and commercial readiness for its investigational gene therapy, detalimogene voraplasmid, if approved. 17 July 2026
Biotechnology
USA-based biotech company Prolynx has expanded its senior leadership, appointing Simon Harnest as chief financial officer and Amer Mirza as chief scientific officer, as the Emeryville, California, firm pushes a portfolio of long-acting obesity and metabolic disease candidates toward first-in-human testing. 16 July 2026
Biotechnology
Swedish biologics company Simris Group has appointed former Heidelberg Pharma chief executive Andreas Pahl to lead its German subsidiary, Simris Biologics, as it works to advance its antibody-drug conjugate (ADC) payload platform. 15 July 2026
Biotechnology
The German-listed group behind personalized-genetics firm Novogenia has taken its best-known brand as its corporate name, a move it says unifies identity without changing strategy. 15 July 2026
Biosimilars
Swiss generics and biosimilars company Sandoz has announced a set of senior leadership changes designed to sharpen its operations and dealmaking ahead of what it calls a "golden decade" of branded-drug patent expiries. 15 July 2026
Pharmaceutical
UK headquartered ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights in the respiratory clinical development space, has completed a major corporate repositioning and reorganization. The move marks the next stage of the company's development. 14 July 2026
Biotechnology
UK clinical-stage biotech Elevara Medicines today announced the appointment of Mai-Britt Zocca as chief executive (CEO), effective 1 July 2026. Dr Zocca succeeds founder and CEO Emma Tinsley and will lead the company into its next phase of growth. 14 July 2026
Biotechnology
Boston, USA-based clinical-stage biotech Cue Biopharma has announced the appointment of Dr Dominic Borie as chief medical officer (CMO) and head of R&D. 14 July 2026
Pharmaceutical
US pharma major Pfizer has changed the leadership of its obesity discovery group, with Danna Breen appointed vice president and head of obesity discovery following the departure of longtime scientific leader Kendra Bence. 13 July 2026
Biotechnology
US RNA medicines focused biotech Stoke Therapeutics today announced that Thomas McCauley has been appointed chief scientific officer (CSO). 13 July 2026
Biotechnology
Heidelberg, Germany-based research institute BioMed X and German drug major Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s US R&D headquarters in Ridgefield, Connecticut. 9 July 2026
Pharmaceutical
San Diego, USA-based ARS Pharmaceuticals has announced a chief executive (CEO) succession, in which co-founder and CEO Richard Lowenthal will no longer serve as an employee and officer of the company effective July 6, 2026. 9 July 2026
Pharmaceutical
Dutch contract research, development and manufacturing organization (CRDMO) Symeres and Axxam, a provider of biology-driven discovery services, today announced the appointment of Russell Thomas as chief scientific officer to drive a joint collaboration between Symeres and Axxam that combines the unique R&D services offering of both organizations. 8 July 2026
Biotechnology
US precision oncology biotech Stipple Bio has appointed Roland Gendron as chief business officer as it prepares to move lead candidate STP-100 into early clinical studies. 8 July 2026
Pharmaceutical
Florida, USA-based clinical-stage biopharma DemeRx has appointed Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from pre-clinical research through clinical development. 8 July 2026
Pharmaceutical
UK biotech Levicept, which is focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announced the appointment of Darlene Deptula-Hicks as chief financial officer (CFO). 7 July 2026
Biotechnology
Indian contract research, development and manufacturing organization Syngene International has appointed Siddharth Mittal as managing director and chief executive. 3 July 2026
Biotechnology
Swiss privately-held late-stage biotechnology company Anaveon has appointed Laetitia Pouzol as chief scientific officer. 3 July 2026
Biotechnology
Polish biologics contract development and manufacturing organization (CDMO) Rezon Bio has appointed Hubert Scholze as chief business officer, bringing in an executive with more than 25 years of experience in biologics manufacturing and commercial operations as the company expands its international presence. 2 July 2026
Biotechnology
Swiss biopharmaceutical company Idorsia has appointed Roland Wandeler as chief executive officer, effective October 1, as it looks to build on a recent financial turnaround and accelerate growth across its commercial portfolio and late-stage pipeline. 1 July 2026
Biotechnology
UK biotech company Exonate has appointed Olav Hellebø as chief executive, as it prepares to start a Phase IIb trial of its lead diabetic eye disease candidate, EXN407. 30 June 2026
Biotechnology
Danish biotech company Muna Therapeutics has named Michel Detheux as chief executive as it prepares to move its lead Alzheimer’s disease candidate toward Phase II testing. 30 June 2026
Biotechnology
Finnish clinical-stage biotech Aplagon has appointed pharmaceutical industry veteran Carl Lindgren as chair of its board of directors as the company prepares to advance its lead thrombo-inflammatory therapy into later-stage development. 30 June 2026
Biotechnology
US clinical-stage biotech Kailera Therapeutics, which is focused on elevating the next era of obesity care, has announced the appointment of Kathleen Tregoning as chief corporate affairs officer. 30 June 2026
Biotechnology
Candel Therapeutics has appointed oncology commercial veteran Mark Sims as chief commercial officer, effective July 6, as the company prepares for the potential launch of its lead cancer immunotherapy, aglatimagene besadenovec (CAN-2409), for localized prostate cancer. 26 June 2026
Pharmaceutical
Japanese pharma Takeda has formally appointed Julie Kim as president and chief executive, completing an 18-month leadership transition at the country’s largest drugmaker. 25 June 2026
Pharmaceutical
Germany’s Merck, which operates its Healthcare business sector as EMD Serono in the USA and Canada, today announced that Miguel Fernández Alcalde has been appointed head of global commercial strategy. 25 June 2026
Pharmaceutical
Danish CNS specialist Lundbeck has appointed Tarek Samad as executive vice president and head of Research & Development (R&D) and will join the executive leadership Team (ELT) effective 1 September 2026. 24 June 2026
Pharmaceutical
French pharma major Sanofi today announced the appointment of Paulo Fontoura as executive vice president, global head of research & development pharma, effective September 1, 2026. 22 June 2026
Pharmaceutical
UK specialty pharmaceutical company Essential Pharma has named Becki Morison as chief executive officer, effective July 1, as it looks to expand its rare disease and established brands businesses. 19 June 2026
Pharmaceutical
US pharma giant Pfizer is looking for a new chief financial officer after Dave Denton decided to leave the company for a role outside pharma. 19 June 2026
Biotechnology
German neuroscience company HMNC Brain Health has appointed former Lundbeck executive Bjørn Grønning as chief medical officer as it prepares two depression programs for Phase III-readiness activities. 17 June 2026
Biotechnology
Moderna today announced changes to its operating model to support its short- and long-term business goals, with the news sending the US mRNA vaccines firm’s shares up 3.5% to $53.97 by mid-morning. 16 June 2026
Pharmaceutical
US biotech Conexeu Sciences has added three directors to its board and named co-founder David Bogart as chief commercial officer, as the newly listed company looks to put more commercial muscle behind its regenerative tissue platform. 16 June 2026
Biotechnology
New Jersey, USA-based biotech Reunion Neuroscience has appointed Dr Sahil Kirpekar as its new president, chief executive (CEO) and a member of the board of Ddirectors, effective immediately. 16 June 2026
Biotechnology
Sweden’s Hansa Biopharma announced today the appointment of Adam Cutler as chief financial officer (CFO) and a member of the executive committee, effective June 22, 2026. 15 June 2026
Pharmaceutical
Canada-based clinical-stage drug developer ZYUS Life Sciences Corporation yesterday announced a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. 12 June 2026
Biotechnology
Spanish women’s health biotech company Oriva Therapeutics has appointed Agnès Arbat as chief executive, as it advances a pipeline of treatments for chronic gynecological diseases led by the Phase I endometriosis candidate ORV-362. 11 June 2026
Biotechnology
UK biotech PhoreMost today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. 10 June 2026
Biotechnology
German biotech CatalYm has appointed Peter Garcia as chief financial officer, adding a seasoned life sciences finance executive as its lead asset, visugromab, moves through a broad mid- to late-stage clinical program. 10 June 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze